26
|
Chouaïd C, Debieuvre D, Durand-Zaleski I, Fernandes J, Scherpereel A, Westeel V, Blein C, Gaudin A, Ozan N, Leblanc S, Vainchtock A, Cotté F, Souquet P. Disparités régionales et socio-économiques dans le cancer du poumon (étude TERRITOIRE). Rev Mal Respir 2016. [DOI: 10.1016/j.rmr.2015.10.047] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
27
|
Souquet P, Debieuvre D, Westeel V, Durand-Zaleski I, Fernandes J, Scherpereel A, Blein C, Gaudin A, Ozan N, Vainchtock A, Saitta B, Cotté F, Chouaïd C. Délais d’accès à la chimiothérapie adjuvante après une chirurgie curative dans le cancer du poumon (étude TERRITOIRE). Rev Mal Respir 2016. [DOI: 10.1016/j.rmr.2015.10.112] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
28
|
Cadranel J, Quoix E, Duruisseaux M, Friard S, Fabre E, Daniel C, Westeel V, Madroszyk A, Léna H, Merle P, Mazières J, Dansin E, Scherpereel A, Hiret S, Coudert B, Souquet P, Wislez M, Morin F, Zalcman G, Barlesi F, Missy P. Valeur pronostique du statut moléculaire de KRAS, EGFR et ALK dans la cohorte prospective IFCT-PREDICT.amm de carcinomes bronchiques non à petites cellules (CBNPC) étendus, non préalablement traités. Rev Mal Respir 2016. [DOI: 10.1016/j.rmr.2015.10.049] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
29
|
Cadranel J, Quoix E, Duruisseaux M, Friard S, Fabre E, Daniel C, Westeel V, Madroszyk A, Lena H, Merle P, Mazieres J, Dansin E, Scherpereel A, Hiret S, Coudert B, Souquet P, Missy P, Morin F, Zalcman G, Barlesi F. 3128 EGFR, ALK, KRAS prognostic value in a large French prospective cohort of non-previously treated advanced NSCLC. Preliminary report of the IFCT-PREDICT.amm cohort. Eur J Cancer 2015. [DOI: 10.1016/s0959-8049(16)31769-5] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
30
|
Munck C, Mordon S, Scherpereel A, Porte H, Dhalluin X, Betrouni N. Dosimetry optimization of intrapleural photodynamic therapy for malignant pleural mesothelioma. Photodiagnosis Photodyn Ther 2015. [DOI: 10.1016/j.pdpdt.2015.07.024] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
31
|
Vanparis T, Akkad R, Carnaille B, Scherpereel A, Dhalluin X. Métastases surrénaliennes dans les cancers bronchopulmonaires non à petites cellules, épidémiologie et prises en charges médicales. Rev Mal Respir 2015. [DOI: 10.1016/j.rmr.2014.10.667] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
32
|
Moro-Sibilot D, Scherpereel A, Mennecier B, Otto J, Mazières J, Clement-Duchene C, Yurasov S, Zimmermann A, Cuyun Carter G, Garon EB, Pérol M. REVEL : étude randomisée de phase III, en double insu, évaluant l’association docétaxel (D)-ramucirumab (R) versus D plus placebo (P) en deuxième ligne de traitement du CBNPC de stade IV. Rev Mal Respir 2015. [DOI: 10.1016/j.rmr.2014.10.066] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
33
|
Scherpereel A, Cornelissen R, Di Pietro A, Kindler H, Nackaerts K, Antonia S, Calabrò L, Fu D, Robbins P, Ibrahim R, Maio M. Randomized, Double-Blind, Placebo-Controlled Study of Tremelimumab for Second-Line and Third-Line Treatment of Unresectable Pleural or Peritoneal Mesothelioma. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu342.27] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
34
|
Blum TG, Rich A, Baldwin D, Beckett P, De Ruysscher D, Faivre-Finn C, Gaga M, Gamarra F, Grigoriu B, Hansen NCG, Hubbard R, Huber RM, Jakobsen E, Jovanovic D, Konsoulova A, Kollmeier J, Massard G, McPhelim J, Meert AP, Milroy R, Paesmans M, Peake M, Putora PM, Scherpereel A, Schonfeld N, Sitter H, Skaug K, Spiro S, Strand TE, Taright S, Thomas M, van Schil PE, Vansteenkiste JF, Wiewrodt R, Sculier JP. The European initiative for quality management in lung cancer care. Eur Respir J 2014; 43:1254-77. [DOI: 10.1183/09031936.00106913] [Citation(s) in RCA: 33] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
35
|
Barlesi F, Scherpereel A, Gorbunova V, Gervais R, Vikström A, Chouaid C, Chella A, Kim JH, Ahn MJ, Reck M, Pazzola A, Kim HT, Aerts JG, Morando C, Loundou A, Groen HJM, Rittmeyer A. Maintenance bevacizumab-pemetrexed after first-line cisplatin-pemetrexed-bevacizumab for advanced nonsquamous nonsmall-cell lung cancer: updated survival analysis of the AVAPERL (MO22089) randomized phase III trial. Ann Oncol 2014; 25:1044-52. [PMID: 24585722 DOI: 10.1093/annonc/mdu098] [Citation(s) in RCA: 131] [Impact Index Per Article: 13.1] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
BACKGROUND The randomized, phase III AVAPERL trial evaluated the safety and efficacy of bevacizumab maintenance with or without pemetrexed in nonsquamous nonsmall-cell lung cancer (nsNSCLC). Progression-free survival (PFS) was significantly prolonged with bevacizumab-pemetrexed, but overall survival (OS) data were immature. In this article, we report an independent, updated analysis of survival outcomes in AVAPERL. PATIENTS AND METHODS Patients with advanced nsNSCLC received first-line bevacizumab (7.5 mg/kg), cisplatin (75 mg/m(2)), and pemetrexed (500 mg/m(2)) every 3 weeks (q3w) for four cycles. Nonprogressing patients were randomized to maintenance bevacizumab (7.5 mg/kg) or bevacizumab-pemetrexed (500 mg/m(2)) q3w until progression or consent withdrawal. The primary end point of the trial was PFS; in this independent OS analysis, participating study centers were contacted to collect survival data on patients still alive at the time of the first analysis. RESULTS A total of 376 patients received induction treatment. Disease control was confirmed in 71.9% of patients; 253 patients were randomized to maintenance treatment with bevacizumab (n = 125) or bevacizumab-pemetrexed (n = 128). At a median follow-up of 14.8 months, patients allocated to bevacizumab-pemetrexed had significantly improved PFS versus those on bevacizumab when measured from randomization [7.4 versus 3.7 months, hazard ratio (HR), 0.57, 95% confidence interval (CI) 0.44-0.75); P < 0.0001]. OS events occurred in 58% of all patients. OS was numerically longer with bevacizumab-pemetrexed versus bevacizumab when measured from randomization [17.1 versus 13.2 months, HR 0.87 (0.63-1.21); P = 0.29]. Second-line therapy was administered in 77% and 70% of patients in the bevacizumab and bevacizumab-pemetrexed arms, respectively. No new adverse events were reported during this updated analysis. CONCLUSION In an unselected population of nsNSCLC patients achieving disease control on platinum-based induction therapy, maintenance with bevacizumab-pemetrexed was associated with a nonsignificant increase in OS over bevacizumab alone.
Collapse
|
36
|
Galateau-Sallé F, Gilg Soit Ilg A, Le Stang N, Brochard P, Pairon J, Astoul P, Frenay C, Blaizot G, Chamming's S, Ducamp S, Rousvoal T, de Quillacq A, Abonnet V, Abdalsamad I, Begueret H, Brambilla E, Capron F, Copin M, Danel C, de Lajartre A, Foulet-Roge A, Garbe L, Groussard O, Giusiano S, Hofman V, Lantuejoul S, Piquenot J, Rouquette I, Sagan C, Thivolet-Bejui F, Vignaud J, Scherpereel A, Jaurand M, Jean D, Hainaut P, Chérié-Challine L, Goldberg M, Luce D, Imbernon E. Mésothéliome : les dispositifs en place en France « le réseau mésothéliome » 1998–2013. Ann Pathol 2014; 34:51-63. [DOI: 10.1016/j.annpat.2014.01.009] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/11/2014] [Accepted: 01/13/2014] [Indexed: 12/30/2022]
|
37
|
Vannimenus-Hayem C, Scherpereel A, Chevalier D, Lefebvre G, Dansin E, Lafitte J, Pasquesoone X, Lefebvre J, Rolland B, Pavy-Bricout H. Suivi des consommations de tabac et d’alcool après un premier cancer du poumon ou des voies aériennes supérieures : état des lieux à la fin des inclusions de l’étude Altak. Rev Mal Respir 2014. [DOI: 10.1016/j.rmr.2013.10.388] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
38
|
Barlesi F, Gervais R, Chouaid C, Souquet P, Milleron B, Monnet I, Étienne-Mastroiani B, Berard H, Deplanque G, Zalcman G, Domas J, Pichon E, Janicot H, Perol M, Shott R, Vaylet F, Genet D, Moro-Sibilot D, Fournel P, Falchero L, Morando C, Loundou A, Scherpereel A. Chimiothérapie (CT) de maintenance par bevacizumab/pemetrexed chez des patients (pts) avec un cancer bronchique non à petites cellules non épidermoïdes (CBNPCne) avancé : survie globale actualisée de l’essai randomisé de phase III AVAPERL. Rev Mal Respir 2014. [DOI: 10.1016/j.rmr.2013.10.042] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
39
|
Veillon R, Willemin M, Scherpereel A, Zalcman G, Galateau-Salle F, Brochard P, Chomy F, Begueret H, Raherison C, Mazieres J. Étude multicentrique du mésothéliome pleural de la femme. Rev Mal Respir 2014. [DOI: 10.1016/j.rmr.2013.10.079] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
40
|
Héron C, Cusseau M, Danel Buhl N, Lafitte JJ, Scherpereel A, Cortot A, Porte H, Desbordes J, Séguy D, Seignez-Dartois B. O51 Soin diététique coordonné, impact d’une prise en charge précoce ? NUTR CLIN METAB 2013. [DOI: 10.1016/s0985-0562(13)70323-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
41
|
Ramalingam S, Crawford J, Chang A, Manegold C, Perez-Soler R, Douillard JY, Thatcher N, Barlesi F, Owonikoko T, Wang Y, Pultar P, Zhu J, Malik R, Giaccone G, Della-Fiorentina S, Begbie S, Jennens R, Dass J, Pittman K, Ivanova N, Koynova T, Petrov P, Tomova A, Tzekova V, Couture F, Hirsh V, Burkes R, Sangha R, Ambrus M, Janaskova T, Musil J, Novotny J, Zatloukal P, Jakesova J, Klenha K, Roubec J, Vanasek J, Fayette J, Barlesi F, Bennouna-Louridi J, Chouaid C, Mazières J, Vallerand H, Robinet G, Souquet PJ, Spaeth D, Schott R, Lena H, Martinet Y, El Kouri C, Baize N, Scherpereel A, Molinier O, Fuchs F, Josten K, Manegold C, Marschner N, Schneller F, Overbeck T, Thomas M, von Pawel J, Reck M, Schuette W, Hagen V, Schneider CP, Georgoulias V, Varthalitis I, Zarogoulidis K, Syrigos K, Papandreou C, Bocskei C, Csanky E, Juhasz E, Losonczy G, Mark Z, Molnar I, Papai-Szekely Z, Tehenes S, Vinkler I, Almel S, Bakshi A, Bondarde S, Maru A, Pathak A, Pedapenki R, Prasad K, Prasad S, Kilara N, Gorijavolu D, Deshmukh C, John S, Sharma L, Amoroso D, Bajetta E, Bidoli P, Bonetti A, De Marinis F, Maio M, Passalacqua R, Cascinu S, Bearz A, Bitina M, Brize A, Purkalne G, Skrodele M, Baba A, Ratnavelu K, Saw M, Samson-Fernando M, Ladrera G, Jassem J, Koralewski P, Serwatowski P, Krzakowski M, Cebotaru C, Filip D, Ganea-Motan D, Ianuli C, Manolescu I, Udrea A, Burdaeva O, Byakhov M, Filippov A, Lazarev S, Mosin I, Orlov S, Udovitsa D, Khorinko A, Protsenko S, Chang A, Lim H, Tan Y, Tan E, Bastus Piulats R, Garcia-Foncillas J, Valdivia J, de Castro J, Domine Gomez M, Kim S, Lee JS, Kim H, Lee J, Shin S, Kim DW, Kim YC, Park K, Chang CS, Chang GC, Goan YG, Su WC, Tsai CM, Kuo HP, Benekli M, Demir G, Gokmen E, Sevinc A, Crawford J, Giaccone G, Haigentz M, Owonikoko T, Agarwal M, Pandit S, Araujo R, Vrindavanam N, Bonomi P, Berg A, Wade J, Bloom R, Amin B, Camidge R, Hill D, Rarick M, Flynn P, Klein L, Lo Russo K, Neubauer M, Richards P, Ruxer R, Savin M, Weckstein D, Rosenberg R, Whittaker T, Richards D, Berry W, Ottensmeier C, Dangoor A, Steele N, Summers Y, Rankin E, Rowley K, Giridharan S, Kristeleit H, Humber C, Taylor P. Talactoferrin alfa versus placebo in patients with refractory advanced non-small-cell lung cancer (FORTIS-M trial). Ann Oncol 2013; 24:2875-80. [DOI: 10.1093/annonc/mdt371] [Citation(s) in RCA: 41] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
42
|
Berghmans T, Ameye L, Willems L, Paesmans M, Mascaux C, Lafitte JJ, Meert AP, Scherpereel A, Cortot AB, Cstoth I, Dernies T, Toussaint L, Leclercq N, Sculier JP. Identification of microRNA-based signatures for response and survival for non-small cell lung cancer treated with cisplatin-vinorelbine A ELCWP prospective study. Lung Cancer 2013; 82:340-5. [PMID: 24007627 DOI: 10.1016/j.lungcan.2013.07.020] [Citation(s) in RCA: 49] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/19/2013] [Revised: 07/16/2013] [Accepted: 07/21/2013] [Indexed: 01/12/2023]
Abstract
UNLABELLED Clinical variables, like stage and performance status (PS), have predictive and prognostic values in advanced non-small cell lung cancer (NSCLC) patients treated with chemotherapy, not allowing adequate individual prediction. MicroRNA (miRNA) are non-coding RNAs regulating gene expression. In a prospective study, we assessed the predictive value for response and survival of tumour miRNA in NSCLC patients treated by 1st line cisplatin and vinorelbine. miRNA expression was analysed on a biopsy obtained during the diagnostic bronchoscopy, using TaqMan Low Density Arrays. The signature for response was derived using logistic regression with stepwise variable selection. The associations between overall survival and miRNA expression levels were estimated by using the Kaplan-Meier method, log-rank test, and Cox proportional hazard regression models to estimate the hazard ratios. In total, 38 patients with adequate tumour biopsies, treated with cisplatin-vinorelbine were included: male (n = 27), 80-100 Karnofsky PS (n = 27), adenocarcinoma (n = 20), stage IV (n = 30). One patient was considered not assessable for response but remained included in the survival analyses. Out of the 37 patients assessable for response, 16 partial responses (43%) were observed. A two miRNA signature (miR-149 and miR-375) was found predictive for response and was also associated to progression-free survival (p = 0.05). Using a linear combination of the miR CT values with Cox's regression coefficients as weights, we constructed a prognostic score for overall survival including four miRNA (miR-200c, miR-424, miR-29c and miR-124). The signature distinguished patients with good (n = 18) and poor (n = 20) prognosis with respective median survival times of 47.3 months (95% CI 29.8-52.4) and 15.5 months (95% CI 9.1-22.8) (p < 0.001; hazard ratio 21.1, 95% CI 4.7-94.9). CONCLUSIONS miRNA signature allows predicting response and is of prognostic value for survival in patients with NSCLC treated with first line cisplatin and vinorelbine.
Collapse
|
43
|
Massongo M, Leroy S, Scherpereel A, Vaniet F, Dhalluin X, Chahine B, Sanfiorenzo C, Genin M, Marquette CH. Outpatient management of primary spontaneous pneumothorax: a prospective study. Eur Respir J 2013; 43:582-90. [DOI: 10.1183/09031936.00179112] [Citation(s) in RCA: 51] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
44
|
Tonnel AB, Wallaert B, Lafitte JJ, Scherpereel A. À la mémoire d’Isabelle Tillie-Leblond. Rev Mal Respir 2013. [DOI: 10.1016/j.rmr.2013.05.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
45
|
Boulanger S, Delattre C, Descarpentries C, Escande F, Bouchindhomme B, Copin MC, Dhalluin X, Scherpereel A, Ramon PP, Cortot A, Fournier C. Faisabilité de la recherche de mutations EGFR et KRAS sur des prélèvements obtenus par EBUS-PTBA. Rev Mal Respir 2013; 30:351-6. [DOI: 10.1016/j.rmr.2012.12.013] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/12/2012] [Accepted: 12/10/2012] [Indexed: 10/27/2022]
|
46
|
Wibmer T, Berghmans T, Kropf-Sanchen C, Lafitte JJ, Stoiber K, Paesmans M, Rüdiger S, Scherpereel A, Blanta I, Rottbauer W, Sculier JP, Schumann C. Histologie als potenzieller klinischer Prediktor in der Behandlung des fortgeschrittenen nichtkleinzelligen Bronchialkarzinoms (NSCLC) mit Vinorelbin und Mitomycin (VM). Pneumologie 2013. [DOI: 10.1055/s-0033-1334768] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
47
|
Delourme J, Dhalluin X, Cortot AB, Lafitte JJ, Scherpereel A. [Malignant pleural mesothelioma: diagnosis and treatment]. REVUE DE PNEUMOLOGIE CLINIQUE 2013; 69:26-35. [PMID: 23333048 DOI: 10.1016/j.pneumo.2012.12.003] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/06/2012] [Revised: 11/30/2012] [Accepted: 12/14/2012] [Indexed: 06/01/2023]
Abstract
Malignant pleural mesothelioma (MPM) is a rare and aggressive tumor issued from the mesothelial surface of the pleural space. A previous exposure to asbestos is the main risk factor of mesothelioma. Clinical signs are most of the time late and unspecific. Chest CT-scan, a key imaging procedure, usually shows a (unilateral) pleurisy associated with pleural nodular thickening. PET-scan associated with CT-scan may help to differenciate MPM from pleural benign tumors but it is not recommended for the diagnosis of MPM, as well as chest resonance magnetic imaging and blood or pleural fluid biomarkers, including soluble mesothelin still under investigation. The diagnosis of MPM is based on histology using essentially immunohistochemistry on pleural biopsies best obtained by thoracoscopy. The treatment of MPM relies mostly on chemotherapy. Surgery, pleurectomy/decortication or extrapleural pneumonectomy, is not recommended outside a clinical trial, as well as adjuvant chest radiotherapy. Prophylactic irradiation of chest scars and drains, validated by the French guidelines in 2005, is however highly discussed at the international level. Finally, numerous research studies presently assess the value of targeted therapies and biomarkers in MPM, opening new perspectives in the management of this cancer.
Collapse
|
48
|
Baranzelli A, Akkad R, Bouchindhomme B, Tacelli N, Delourme J, Dhalluin X, Lafitte JJ, Scherpereel A, Remy-Jardin M, Cortot AB. [Castleman's disease: unusual presentation of Castleman's disease and review of literature]. REVUE DE PNEUMOLOGIE CLINIQUE 2013; 69:55-59. [PMID: 23374393 DOI: 10.1016/j.pneumo.2012.12.005] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/16/2012] [Revised: 12/20/2012] [Accepted: 12/20/2012] [Indexed: 06/01/2023]
Abstract
Castleman disease is a rare disorder of the lymphoid system which can be classified into two clinical groups, monocentric disease versus multicentric disease, and two histological types, the hyaline vascular form versus the plasma cell form. We report three cases of monocentric Castleman disease. The first one is a classical form of Castleman's disease. The second one is characterized by an uncommon radiological presentation, with a calcification within the tumor. The third one is a plasma cell form with monoclonal proliferation associated with a monoclonal gammapathy. These three cases highlight the polymorphic clinical and radiological features of Castleman disease. They underlie the difficulty of surgical resection due to the tumor vascularization. Other diagnosis hypothesis and associated diseases will also be discussed (HIV, Kaposi's sarcoma, POEMS syndrome).
Collapse
|
49
|
Taverne J, Delourme J, Dhalluin X, Copin MC, Scherpereel A, Lafitte JJ, Cortot AB. [Should elevated beta-HCG levels be an exclusion criteria in clinical trials? A case report of paraneoplastic secretion associated with lung adenocarcinoma]. REVUE DE PNEUMOLOGIE CLINIQUE 2013; 69:36-40. [PMID: 23337393 DOI: 10.1016/j.pneumo.2012.12.002] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/13/2012] [Revised: 12/10/2012] [Accepted: 12/14/2012] [Indexed: 06/01/2023]
Abstract
We report the case of a 55-year-old woman with pulmonary adenocarcinoma and bone metastases who was diagnosed with paraneoplastic secretion of the beta subunit of human chorionic gonadotropin (beta-HCG) while being screened for inclusion in a clinical trial. Immunohistochemistry analysis of a bone biopsy revealed strong staining of cancer cells with anti-beta HCG antibodies. Serial measurements of circulating Beta HCG seemed to be influenced by antineoplastic treatments, although they were not strictly associated with tumour evolution assessed by CT scans. Little is known about paraneoplastic secretion of beta HCG, although it has been found in 12% to 24% of non-small cell lung cancers. Usefulness of serial measurements of beta HCG for monitoring NSCLC has yet to be demonstrated, but its use as a criterion for inclusion in clinical trials needs to be questioned.
Collapse
|
50
|
Scherpereel A, Cortot A. [Frequent and less frequent paraneoplastic syndromes in lung cancer]. Rev Mal Respir 2013; 30:13-4. [PMID: 23318183 DOI: 10.1016/j.rmr.2012.12.010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/07/2012] [Accepted: 12/10/2012] [Indexed: 10/27/2022]
|